David C. Schwartz

Partner

David C. Schwartz advises a broad range of clients in the life sciences, healthcare, and technology industries. David’s practice focuses on capital markets transactions, SEC reporting and compliance, mergers and acquisitions (M&A), deSPACs and other strategic transactions, private equity and venture capital transactions, and corporate governance matters. He works with clients of all sizes, including startups and growth businesses, publicly held middle-market companies, venture capital firms, strategic investors, and underwriters. David leads the corporate and business transactions practice in the Princeton office and holds leadership positions in the firm’s capital markets public company practice and biotech and beyond industry team.

David regularly advises clients in connection with initial public offerings (IPOs), follow-on offerings, at-the-market offerings (ATMs), private investments in public equity (PIPEs), and registered direct offerings, in addition to venture capital, private equity, M&A, going-private, and other strategic transactions. He also acts as counsel for both public and private companies at various stages of development, providing general corporate representation and advice to boards of directors and management concerning corporate governance matters.

David previously practiced as an associate at Morgan Lewis, and returned to the firm in 2019 after working as a partner at another global law firm and helping to establish its New Jersey office. There, he served as a member of its national leadership group of the US emerging growth and venture capital practice.

David is a frequent panelist on topics involving venture capital, public offerings, corporate governance, and M&A transactions. While attending law school, David worked in the Enforcement Division of the US Securities and Exchange Commission’s Philadelphia regional office.

Villanova University School of Law, 2001, J.D.
Lafayette College, 1998, B.A., with honors

New Jersey
New York

Listed, Top 25 Biotechnology and Life Sciences Attorneys, Attorney Intel (2024)

Recommended, Finance: Capital markets: equity offerings, The Legal 500 US (2024)

Listed, LMG Life Sciences Awards Americas, Life Sciences Star, Venture Capital (2023, 2024)

Listed, New Jersey Law Journal, Dealmaker of the Year (2022)

Listed, IFLR1000 Financial and Corporate, Highly Regarded – State (2022)

Ranked, Corporate/M&A, New Jersey, Chambers USA (2020–2024)

Recommended, Industry focus: Healthcare: life sciences, The Legal 500 US (2020)

Recommended, M&A/corporate and commercial: M&A: large deals ($1bn+), The Legal 500 US (2020)

Ranked, Chambers USA (2018, 2019)

Recommended, The Legal 500 US (2018)

Listed, NJBIZ, Top Forty Under 40, New Jersey (2015)

Listed, New Jersey Super Lawyers, Rising Star (2013–2015)

Member, American Bar Association

Member, New Jersey Bar Association

No aspect of this advertisement has been approved by the Supreme Court of New Jersey. A description of the selection methodology for the above awards can be found here.